Wire · opportunities
CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric population
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
The FDA has approved Bristol Myers Squibb's CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adults and pediatric patients weighing 30 kg or more, based on positive results from the Phase 3 SCOUT-HCM trial. CAMZYOS is now the only FDA-approved therapy for pediatric oHCM and has the broadest indication among cardiac myosin inhibitors.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
You have a new FDA-approved treatment option to address pediatric obstructive hypertrophic cardiomyopathy, opening access to a previously unmet patient group. This regulatory milestone lets you target young patients with a therapy that directly improved key heart function measures in trials.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics